Rising Covid cases in China a concern but India need not panic: SII CEO

Serum Institute of India CEO Adar Poonawalla expressed concern over reports of a rising Covid-19 graph in China but said there is no need to panic as the vaccination coverage in India is excellent

Adar Poonawalla, CEO, Serum Institute
Adar Poonawalla, CEO, Serum Institute
Press Trust of India Pune
1 min read Last Updated : Dec 21 2022 | 10:45 PM IST

Serum Institute of India (SII) CEO Adar Poonawalla on Tuesday expressed concern over reports of a rising COVID-19 graph in China but said there is no need to panic as the vaccination coverage in India is excellent.

Poonawalla's tweet came a day after the Union Health Ministry urged all states and UTs to ramp up the whole genome sequencing of positive samples to keep track of newer variants, if any, amid a spurt in cases in the US and China.

"The news of rising COVID cases coming out of China is concerning, we need not panic given our excellent vaccination coverage and track record. We must continue to trust and follow the guidelines set by the Government of India and @MoHFW_INDIA," Poonawalla tweeted.

During the COVID-19 pandemic, the Pune-based SII had collaborated with Oxford University and pharmaceutical company Astra Zeneca for making the Covishield vaccine.

In October, Pooanwalla said the SII stopped producing the vaccine in December 2021. Of the total stock available at that time, about 100 million doses had already expired, he had said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusSerum Institute of IndiaChina

First Published: Dec 21 2022 | 2:57 PM IST

Next Story